Verve Therapeutics Holds Annual Stockholders Meeting

The latest update is out from Verve Therapeutics ( (VERV) ).

On June 5, 2025, Verve Therapeutics held its Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Lonnel Coats, Jodie Morrison, and Krishna Yeshwant, M.D. as Class I directors for a three-year term. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified, and the compensation for the company’s named executive officers was approved on an advisory basis.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.

Spark’s Take on VERV Stock

According to Spark, TipRanks’ AI Analyst, VERV is a Neutral.

Verve Therapeutics’ stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company’s robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.

To see Spark’s full report on VERV stock, click here.

More about Verve Therapeutics

Verve Therapeutics, Inc. operates in the biotechnology industry, focusing on developing gene-editing therapies to treat cardiovascular diseases.

Average Trading Volume: 3,429,363

Technical Sentiment Signal: Hold

Current Market Cap: $552.2M

Learn more about VERV stock on TipRanks’ Stock Analysis page.